InvestorsHub Logo
Followers 827
Posts 119581
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 44

Tuesday, 05/03/2022 1:56:52 PM

Tuesday, May 03, 2022 1:56:52 PM

Post# of 128
ZBH 1Q22 results—2022 guidance:

https://investor.zimmerbiomet.com/news-and-events/news/2022/05-03-2022-113116507

1Q22 sales were +7% YoY in constant currency. 1Q22 non-GAAP EPS was $1.61, excluding the from the ZIMV segment during Jan and Feb, prior to the 3/1/22 spin-off. This compares to $1.71 non-GAAP EPS in 1Q21 (which included the ZIMV segment).

Elective-procedure recovery was stronger than the company expected. In Mar 2022 (but not Jan and Feb), procedure volume was higher than 2019 (pre-pandemic) levels.

2022 non-GAAP EPS guidance was raised and tightened to $6.65-$6.85 (from the prior range of $6.40-6.80).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ZBH News